| Filed On | Filing |
|---|---|
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
First Patient Dosed in Global Phase 2b ASCENTRA-UC Trial; Topline Results Expected in Q4 2027 |
| 10 Aug 2026 |
8-K: Results of Operations and Financial Condition
Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development |
| 11 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
(a) Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company and any ... |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition
Advancing potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug for treatment of IBD |
| 02 Apr 2026 |
8-K: Other Events
In preparation for the expected Phase 2 study of PALI-2108 for the treatment of patients with moderate to severe Ulcerative Colitis (“UC”), and in order to expedite the enrollment of patients (the “Study Enrollment”), on March 30, 2026, ... |
| 04 Dec 2025 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
Palisade Bio, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Company”), hereby certifies that: |
| 22 Oct 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On September 4, 2025, the Board of Directors of Palisade Bio, Inc. (the “Company”), upon the approval and recommendation of the Compensation Committee, approved and adopted a Phantom Unit Plan (the “Plan”) and related form of Phantom Uni... |
| 20 Oct 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On October 17, 2025, Palisade Bio, Inc. (the “Company”) held its annual meeting of stockholders (“Annual Meeting”). As of September 12, 2025, the record date for the Annual Meeting (“Record Date”), 9,119,152 shares of the Company’s commo... |
| 16 Oct 2025 |
8-K: Other Events
On October 15, 2025, Palisade Bio, Inc. (the “Company”) provided the following corporate and financing updates: |
| 09 Oct 2025 |
8-K: Other Events
Carlsbad, CA — October 9, 2025 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company advancing novel therapeutics for patients living with autoimmune, inflammatory,... |
| 26 Sep 2025 |
8-K: Other Events
On September 26, 2025, Palisade Bio, Inc. (the “Company”) convened and then determined to adjourn, without conducting any business, a special meeting of stockholders (the “Special Meeting”) because the Company did not have a sufficient n... |
| 18 Sep 2025 |
8-K: Other Events
On September 18, 2025, Palisade Bio, Inc. (the “Company”) convened and then determined to adjourn, without conducting any business, a special meeting of stockholders (the “Special Meeting”) because the Company did not have a sufficient n... |
| 05 Sep 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On September 4, 2025 the Board of Directors of Palisade Bio, Inc. (the “Company”), upon the approval and recommendation of the Compensation Committee, approved and adopted a Phantom Unit Plan (the “Plan”) and related form of Phantom Unit... |
| 25 Jul 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UN... |
| 09 Jul 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
Veteran clinical leader with successful track record and experience to help guide the Company’s clinical strategy in Fibrostenotic Crohn’s Disease and Ulcerative Colitis |
| 02 May 2025 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On April 30, 2025, Palisade Bio, Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that for 30 consecutive trading days preceding the date of the Notice, the bid price of... |
| 16 Dec 2024 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
The undersigned, Palisade Bio, Inc., Delaware corporation (collectively with its subsidiaries, including, without limitation, all entities disclosed or described in the Registration Statement as being subsidiaries of Palisade Bio, Inc., ... |
| 27 Sep 2024 |
8-K: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation
This Executive Employment Agreement (the “Agreement”) is made and entered into as of September 25, 2024 (the “Effective Date”), by and between J.D. Finley (“Executive”) and Palisade Bio, Inc. (the “Company”). |
| 08 Jul 2024 |
8-K: Submission of Matters to a Vote of Security Holders
On July 8, 2024, Palisade Bio, Inc. (the “Company”) held its annual meeting of stockholders (“Annual Meeting”). As of May 16, 2024, the record date for the Annual Meeting (“Record Date”), 936,402 shares of the Company’s common stock were... |
| 10 May 2024 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
Wall Street and biotech industry veteran with expertise across corporate finance, business development, M&A, licensing, and strategic alliance transactions, globally |
Loading...